

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-70 (canceled)

Claim 71 (New): A method for transcutaneous immunization comprising:

(a) providing an adjuvant only formulation comprised of at least one adjuvant which is itself antigenic;

wherein the adjuvant is a molecule selected from the group consisting of ADP-ribosylating exotoxins, B subunits of ADP-ribosylating exotoxins and modified ADP-ribosylating exotoxins, wherein the modified exotoxin is catalytically inactivated or modified to be less toxic to the organism than the non-modified exotoxin;

(b) applying said formulation to skin of an organism without penetrating through said skin's dermis layer; and

(c) wherein said formulation induces an antigen-specific immune response in said organism, wherein at least one epitope of said antigen is recognized.

Claim 72 (New): A method of claim 71, wherein said ADP-ribosylating exotoxin selected from the group consisting of *E. coli* heat-labile enterotoxin (LT), cholera toxin (CT), diphtheria toxin (DT), pertussis toxin (PT), and tetanus toxin (TT).

Claim 73 (New): The method of claim 71 further comprising hydrating the skin.

Claim 74 (New): The method of claim 73, wherein hydration enhances the antigen-specific immune response as compared to application of the formulation without hydration.

Claim 75 (New): The method of claim 71, wherein the organism is a human.

Claim 76 (New): The method of claim 71, wherein the formulation is applied in liquid form.

Claim 77 (New): The method of claim 71, wherein the formulation is provided in a form selected from the group consisting of cream, emulsion, gel, lotion, ointment, paste, solution and suspension.

Claim 78 (New): The method of claim 71, wherein the formulation is further provided in a container suitable for immersion or spraying of the organism.

Claim 79 (New): The method of claim 71, wherein the antigen specific immune response is induced after only one application of the formulation to the skin.

Claim 80 (New): The method of claim 71, wherein the formulation is packaged in a unit dosage form which is effective to provide an immune response after one application of the formulation to the skin.

Claim 81 (New): A method for transcutaneous immunization comprising:

- (a) providing a formulation comprised of antigen and adjuvant;  
wherein the adjuvant is selected from the group consisting of ADP-ribosylating exotoxins, B subunits of ADP-ribosylating exotoxins and modified ADP-ribosylating exotoxins,  
wherein the modified exotoxin is catalytically inactivated or  
modified to be less toxic to the organism than the non-modified exotoxin; and,
- (b) applying said formulation to skin of an organism without penetrating through said skin's dermis layer;  
wherein said formulation induces an antigen-specific immune response in said organism,  
wherein at least one epitope of said antigen is recognized.

Claim 82 (New): The method of claim 81, wherein the antigen specific immune response recognizes at least one antigen of a pathogen.

Claim 83 (New): The method of claim 82, wherein the pathogen is selected from the group consisting of a bacterium, a virus, a fungus and a parasite.

Claim 84 (New): A method of claim 83, wherein the virus is selected from the group consisting of live viruses, attenuated viruses, and inactivated viruses.

Claim 85 (New): The method of claim 84, wherein the inactivated virus is heat killed rabies virus.

Claim 86 (New): The method of claim 81, wherein the antigen specific immune response recognizes an antigen selected from the group consisting of influenza virus hemagglutinin (HA), influenza virus nucleoprotein (NP), *Hemophilus influenza* B polysaccharide conjugate (Hib-PS), and *Escherichia coli* colonization factor CS6.

Claim 87 (New): A method of claim 81, wherein said ADP-ribosylating exotoxin selected from the group consisting of *E. coli* heat-labile enterotoxin (LT), cholera toxin (CT), diphtheria toxin (DT), pertussis toxin (PT), and tetanus toxin (TT).

Claim 88 (New): The method of claim 81, further comprising hydrating the skin.

Claim 89 (New): The method of claim 88, wherein hydration enhances the antigen-specific immune response as compared to application of the formulation without hydration.

Claim 90 (New): The method of claim 81, wherein the organism is a human.

Claim 91 (New): The method of claim 81, wherein the formulation is applied in liquid form.

Claim 92 (New): The method of claim 81, wherein the formulation is provided in a form selected from the group consisting of cream, emulsion, gel, lotion, ointment, paste, solution and suspension.

Claim 93 (New): The method of claim 81, wherein the formulation is further provided in a container suitable for immersion or spraying of the organism.

Claim 94 (New): The method of claim 81, wherein the antigen specific immune response is induced after only one application of the formulation to the skin.

Claim 95 (New): The method of claim 81, wherein the formulation is packaged in a unit dosage form which is effective to provide an immune response after one application of the formulation to the skin.